ArticleACR open rheumatology2019
Baseline Description of the Juvenile Localized Scleroderma Subgroup From the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry.
Article in ACR open rheumatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 52 citations in OpenAlex.
- The clinical phenotypes and therapeutic strategies for stiff skin syndrome: a case series with literature review.Orphanet journal of rare diseases · 2025Review
- Interferon-Gamma-Inducible Protein-10 (IP-10) and Tumor Necrosis Factor-α (TNF-α) as Serological Predictors of Active Disease Status in Localized Scleroderma.International journal of molecular sciences · 2024Article
- The Serological Evidence of Positive Rheumatoid Factor in Morphea Patients and Its Relation to Disease Severity.Cureus · 2024Article
- Biomarkers in skin autoimmunity-An update on localised scleroderma.Skin health and disease · 2024Review
- Barriers to care in juvenile localized and systemic scleroderma: an exploratory survey study of caregivers' perspectives.Pediatric rheumatology online journal · 2023Article
- Morphea: The 2023 update.Frontiers in medicine · 2023Review
- Diagnosis and Management of Cutaneous Manifestations of Autoimmune Connective Tissue Diseases.Clinical, cosmetic and investigational dermatology · 2022Review
- Controversy around the morphea.Postepy dermatologii i alergologii · 2021Review
- Genetic Signatures From RNA Sequencing of Pediatric Localized Scleroderma Skin.Frontiers in pediatrics · 2021Article
- The importance of development standards for anchoring vignettes: an illustrative example from pediatric localized scleroderma quality of life.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2020Article
- Overview of Juvenile localized scleroderma and its management.World journal of pediatrics : WJP · 2020Review
- Update on the Systemic Treatment of Pediatric Localized Scleroderma.Paediatric drugs · 2019Review
- Developing comparative effectiveness studies for a rare, understudied pediatric disease: lessons learned from the CARRA juvenile localized scleroderma consensus treatment plan pilot study.Pediatric rheumatology online journal · 2019Observational
- Immunopathogenesis of Pediatric Localized Scleroderma.Frontiers in immunology · 2019Review
- Autoantibodies in Morphea: An Update.Frontiers in immunology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 1 country.
Funding
Abstract
objectiveLocalized scleroderma (LS) is a chronic inflammatory and fibrosing skin disorder. We present baseline data on the juvenile LS (jLS) cohort from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry, a multicenter observational registry of pediatric rheumatologic disorders.
methodsThis is a cross-sectional analysis of children with jLS enrolled in the CARRA Legacy Registry between May 2010 and April 2014. Descriptive statistics were used for demographic, clinical, and laboratory features. Data analysis included two-sample
resultsOf 381 children with jLS, 76% were female and 80% Caucasian. Mean onset age was 8.2 years, with 17% having a 2-year or greater delay to first pediatric rheumatology (PRH) visit. Linear scleroderma was the most common subtype (54%). Antinuclear antibody (ANA) positivity was associated with joint contracture (
conclusionChildren with jLS without joint limitation are referred later, highlighting the insidious onset and need for educating referring providers. Poorer function correlated with muscle atrophy, joint contracture, and limb shortening. ANA positivity and elevated CK or aldolase were associated with muscle atrophy, joint contracture, and/or limb shortening, suggesting predictors of muscle involvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.